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Brief History of Human Papillomaviruses
It was not until the 19th century that genital warts
were viewed as having a viral origin. Though warts
were recognized as infectious as early as the 
ancient Greeks and Romans, genital warts were
grouped together with sexually transmitted dis-
eases such as syphilis or gonorrhea. After it was
demonstrated in the early 1900s that the virus
was transmitted from cell-free filtrates of warts,
papillomaviruses were identified in a number of
vertebrate species, apart from humans.1,2
Some important advances in the 1950s and
1960s included the demonstration that viral rep-
lication was associated with the differentiation
process of the epithelial cells which the virus in-
fected as well as some physicochemical analysis
of papillomavirus virions.3,4 Molecular cloning
led to a renaissance in papillomavirus research
around the 1970s, allowing scientists to clone
papillomavirus genomes. This scientific advance
largely enhanced the study of the biological 
and biochemical properties of papillomaviruses.
Sequencing allowed for the identification of the
open reading frames (ORF) as putative viral genes
and reverse genetics allowed investigators to de-
termine the function of viral genes. This resulted
in a greater interest in papillomavirus research.5–7
Since the bovine papillomavirus type 1 (BPV-1)
was able to induce transformation in rodent cell
lines, it was used as the standard papillomavirus
for initiating such studies.8,9 The molecular clon-
ing of human papillomavirus (HPV) genomes
led to an understanding that multiple HPV geno-
types existed and that the biochemical properties
of some of the nonstructural viral proteins were
different from their counterparts in the BPV-1.10,11
Hence, there was a shift in emphasis towards
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HPV, though the study of animal papillomavirus
continued. The recognition that a subset of HPV
was closely associated with cervical cancer and
the increasing appreciation of the medical im-
portance of HPV12–14 led to the establishment of
HPV as the new model of viral tumorigenesis.
Classification of Papillomaviruses
Polyomaviruses were originally classified to-
gether with papillomaviruses in a family called
Papovaviridae because the viruses shared many
features including an icosahedral capsid com-
posed of 72 pentamers, a nonenveloped virion, a
double-stranded, circular DNA genome, and the
site of viral replication and virion assembly as
the nucleus. A major difference is that the papil-
lomavirus genomes and capsids are larger than
polyomaviruses. Further differences were found
when the genomes were sequenced; it was found
that papillomavirus has no major homologous
regions to polyomavirus and papillomavirus
transcription is unidirectional, unlike polyoma-
viruses. Thus, papillomavirus were later desig-
nated by the International Committee on the
Taxonomy of Viruses as a separate family, the
Papillomaviridae.15 Since each papillomavirus is
specific to the species it infects, there are a few
hundred types of papillomavirus.16 Efforts have
been focused on sequencing the HPV types 
because of the strong association with cervical
cancer. There are 96 fully sequenced HPV types
as of 2004 and at least 100 additional HPV types
are sequenced in part.15
Phylogenetic organization of papillomaviruses
has arisen from sequencing papillomavirus ge-
nomes, though they are more largely classified
according to the species they infect and the sites
or disease with which they may be associated.16
Based on the most highly conserved ORF (i.e. 
the ORF of L1, the major protein in viral struc-
ture) among different papillomaviruses, scien-
tists have organized papillomaviruses according
to its comparative sequence homology. Similar
conservation among other areas of the genome is
seen because papillomaviruses have adjusted 
to the changing environment through point 
mutations rather than recombination with other
papillomaviruses.17 The sequence phylogenetic
data lead us to believe that papillomaviruses
evolved with the host species.18 Even between
the most divergent genomes, the sequence iden-
tity for L1 DNA among papillomaviruses is about
40%. In some cases only a single nucleotide dif-
fers. Such a range in homology has led to the fol-
lowing classifications: genus, species, type, subtype
and variant, from most broad to specific. Figure 1
depicts the phylogenetic tree of papillomaviruses
based on the L1 ORF. There are 12 genera, desig-
nated by the first 12 letters of the Greek alpha-
bet. The L1 DNA of all members of one genera
share at least 60% identity. They share less than
60% identity when compared with another gen-
era. The papillomaviruses within the genera that
share 60–70% identity are designated as a spe-
cies. Within the species, a viral type has about
70–90% identity with other viral types in the
species. Subtypes which share 90–98% identity
and variants which share more than 98% iden-
tity can exist within a type. HPV type 16 has been
examined in great detail due to its medical im-
portance.19 Many variants for HPV-16 have been
identified, whereas few subtypes exist.18
Five of the 12 genera, alpha, beta, gamma,
mu and nu, are HPVs, while the other seven are
animal papillomaviruses. The papillomaviruses
of a certain genus infect hosts, which are closely
related in an evolutionary sense. Therefore, pap-
illomaviruses that infect primates are found in
the same genera that include HPVs; some HPVs
are more closely related to nonhuman primate
papillomaviruses than some other HPV in the
genus. HPVs that are associated with genital and
mucosal cancers, which are of greatest medical
importance, belong to the alpha genus. This group
of papillomaviruses is referred to as the genital-
mucosa types. Cervical cancer is often associated
with particular HPV types, which are designated
as high-risk types and found in species 5, 6, 7, 9
and 11.20,21 HPV type 16, most frequently associ-
ated with cervical cancer, is a member of species 9,
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HPV type 18, the next most commonly associ-
ated type with cervical cancer, is a member of
species 7, and HPV 6, which causes cutaneous
genital warts, is a member of species 10.
Members of species of the alpha genus, HPV 2,
27 and 57, primarily infect nongenital skin. The
viruses from genera beta, gamma, mu and nu
also infect nongenital skin. Beta HPV includes epi-
dermodysplasia verruciformis (EV)-specific HPV
types, meaning those HPV types to which EV pa-
tients have increased susceptibility and which
cause nongenital lesions. Some papillomaviruses,
particularly those of the beta and gamma species,
are commensal agents, or agents which contribute
or act together with another virus to cause lesions,
since they are isolated many times from healthy
skin or hair from humans or animals.16,22
Delta genus papillomaviruses include BPV-1
and other papillomaviruses of ungulates and cause
fibropapillomas. These papillomaviruses induce
productive infection of the epithelium and non-
productive transformation of the underlying
fibroblasts, leading to excessive proliferation of
the dermal fibroblasts.
Lesions Associated with HPVs
A certain subset of papillomaviruses is clearly
implicated in causing oncogenic malignancies in
humans. The relationship of some of these onco-
genic papillomaviruses to their associated cancer
is illustrated in Table 1.23–27 One of the most im-
portant HPV-associated mucosal epithelial can-
cers from the public health perspective is cervical
cancer, which in 2007 was the second most com-
mon female cancer globally. Almost all cases of
cervical cancer are attributable to HPV. Other
HPV-associated cancers include anal, vulvar, vagi-
nal, and penile cancers of the anogenital tract, as
T. Hoory, et al
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Figure 1. Phylogeny of papillomaviruses. Using the L1 open reading frame sequences to classify papillomaviruses and
generate a phylogenetic tree. At the end of each branch is the papillomavirus type, at the end of the first set of semicir-
cular groupings is the species and the end of the second set of larger semicircular groupings is the papillomavirus genus.
Most HPV types are in the alpha-papillomavirus genus, as well as beta, gamma and mu genera. The c-number refers to
potential HPV types. (Adapted with permission from Reference 15.)
well as oral and laryngeal cancers, although HPV
accounts for only a portion of these cancer cases.
HPV infection is commonly at multiple mucosal
sites in men and women.28–30 The multiplicity of
infection increases among immunocompromised
individuals.28,31,32
HPV has also been implicated in the cancers
of the cutaneous squamous cells. Some of these
cancers develop in association with EV, a skin
disease, while others develop in immunosup-
pressed individuals. The percentage of these can-
cers that may be attributable to HPV, however, is
unclear. Other common cancers such as cancer
of the breast, lung, colon, rectum, prostate, and
esophagus have also been associated with HPV,
although a consistent recurrent causal relationship
has not been shown.33 These cancers, excluding
esophageal cancer, do not arise in the stratified
squamous epithelia.
In the well-characterized HPV-attributable can-
cers, tumors develop in the epithelia, generally
several years after the initial infection. For the in-
fection to progress to invasive cancer, persistent
infection is required as well as the continual ex-
pression of some viral genes. However, most in-
fections have a benign outcome because they are
self-limited or, even with persistence, do not
progress to cancer.
The extended time gap between initial infec-
tion and onset of cancer and the relatively minor
fraction of infections that result in cancer sug-
gests that there are other factors, such as those in
the environment or the host, which contribute to
the malignant progression of lesions. A likely en-
vironmental risk factor is exposure to carcinogens
such as ultraviolet (UV) light. UV light may be a
co-carcinogen for EV, for example, as it has been
observed that most EV-associated cutaneous can-
cers occur on sun-exposed skin. UV-mediated
mutagenesis and immunosuppression could act
in synergy with HPV to induce carcinogenesis in
these cases. Another important factor is the im-
mune status of the host. Impaired immune func-
tion is associated with a higher risk of persistent
infection and cancer. Other host factors include
genetic diseases such as Fanconi anemia. Adults
with this disease have a defective DNA repair sys-
tem and a severely increased risk of developing
solid HPV-associated tumors; the risk is reported
as more than 150× for cervical, 700× for head-
and-neck, and 4000× for vulvar cancer.34–36
Burden of Genital HPV Infection and
Cancers
Anogenital tract infections by HPV represent the
most important clinical burden from infection with
HPV types (see Table 2).37 Such infections affect
the genital skin and mucosa, including the vaginal
tract cervix and anal canal. The point prevalence of
HPV DNA at the cervix has been estimated from
women with normal cytology in multiple regions
around the world using sensitive detection meth-
ods. The prevalence is highest in the African con-
tinent at 23.0%, with 15.6% in the Americas, 8.3%
HPV epidemiology
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Table 1. Human and animal papillomavirus-associated cancers
Species Cancer Predominant virus Cofactors Reference
Human Skin cancer in patients with EV HPV types 5, 8 Sunlight, genetic (for review, 
Genital tract cancers HPV types 16, 18, 31, 45 Smoking, other see 23, 24, 25)
Oral & tonsillar cancers HPV type 16 Smoking, alcohol
Malignant progression of RRP HPV types 6, 11 X-irradiation
Cattle Alimentary tract cancers BPV Bracket fern 26
Rabbit Cutaneous cancers CRPV Methylcholanthrene and coal tar 27
(experimentally)
EV = epidermodysplasia verruciformis; HPV = human papillomavirus; RRP = recurrent respiratory papillomatosis; BPV = bovine papillomavirus; CRPV =
cottontail rabbit papillomavirus.
in Asia, and 6.6% in Europe (WHO HPV Infor-
mation Centre, www.who.int/hpvcentre/statistics/
dynamic/ico/SummaryReportsSelect.cfm, last ac-
cessed January 30, 2008). Prevalence estimates
likely vary as a function of the age of the popula-
tion, HIV endemicity, and sexual behaviors. Fewer
data are available on the burden of HPV in men,
though a recent study of college-aged males
(18–23 years) demonstrated a comparably high
HPV prevalence (25.8%) when combining sam-
ples taken from multiple genital sites, including
the glands, penile shaft, and scrotum.
Cervical cancer is the second most common
malignancy among women worldwide, with close
to 500,000 new cases each year and close to half
that number of deaths annually.38,39 Although
cervical cancer occurs across the globe, its fre-
quency is unevenly distributed.40,41 Most cervical
cancer, approximately 80% of all cases, occurs in
developing countries. In these countries, cervical
cancer is the most predominant cancer in women.
Cervical cancer cases in developed countries are
much less frequent. About 12,000 cases in the
United States are diagnosed annually, and about
a third of these cases end in death from this ma-
lignant disease. Its incidence within the US also
varies considerably among different socioeco-
nomic and ethnic groups. The rates of occurrence
among black women, for instance, are double
those of white women.42 These disparities in cer-
vical cancer incidence despite relatively similar
HPV prevalence rates among the general pop-
ulation are largely attributed to differential ac-
cess to successful prevention strategies such as
Papanicolaou (Pap) smear screening and exci-
sional treatment of precursor lesions.
Natural history of genital HPV infection
HPV infection of the genital tract is thought to be
the most common sexually transmitted virus.43–46
The prevalence of HPV infection is age-dependent
in most populations studied.47 Women between
15 and 25 years of age have the highest preva-
lence, which may be about 25–40% of all infec-
tions. Figure 2 shows the incidence rates of HPV
infection and other HPV-associated abnormalities
among different age groups. The decrease in the
rate of HPV infection with increasing age likely
results from some combination of decreased HPV
exposure, self-limited nature of most infections,
and a resistance to re-infection. The cumulative
incidence of genital tract HPV infection in col-
lege aged women is estimated to be nearly 50%
within 3 years of sexual debut, and the lifetime
risk is estimated to be 75% or more.43,48,49 The
age-specific prevalence rate across different pop-
ulations is varied.47,50 Most Western populations
have a decreasing trend for increasing age. How-
ever, studies based on South American popula-
tions have indicated a U-shaped trend in these
regions.51,52 The increase in HPV prevalence in
later life could reflect generational changes in
sexual behavior (a cohort effect), changing sexual
behaviors in midlife resulting in new exposures,
T. Hoory, et al
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Table 2. Human papillomavirus types and 
their clinical association (for review, 
see reference 37)
HPV type Associated malignancy
Genital tract
All genital HPV Subclinical infection
6, 11 Exophytic condyloma 
(any site)
6, 11, 16, 18, 31, Flat condyloma (particularly 
others cervix)
16 Bowenoid papulosis
6, 11 Giant condyloma
Cervical cancer
16, 18, 31, 45 Strong association
6, 11, 16, 18, 31 Moderate association
6, 11, 26, 42, 43, 44, Weak or no association
53, 54, 55, 62, 66
16 Vulvar cancer
16 Penile cancer
Oral cavity
13, 32 Focal epithelial hyperplasia
6, 11, 16 Infection with genital HPV
2 Lesions on lip
16 Oral and tonsillar cancer
6, 11 Recurrent respiratory 
papillomas
6, 11 Conjunctival papillomas
or reactivation of latent HPV infection acquired
at younger ages.22,53,54 One study which examined
the age-specific incidence of HPV in a broad age
range of women found that the incidence of 
HPV does increase in women over the age of 40,
and this increase is associated with new sexual
partners.55
The natural history of genital infection by
HPV in men has not been studied in as much 
detail as has been done in women, reflecting 
the largely subclinical state of HPV infection in
men.56 In general, prevalent infection is decreased
in circumcised men, and cervical cancer risk is 
reduced among women with circumcised part-
ners.57 The cumulative incidence rate of any HPV
infection in male university students aged 18–23
was 62.4% over 24 months of follow-up. These
data reflect the high level of exposure to HPV
around the age of sexual debut, and the relative
ease of transmission. Studies from the same uni-
versity cohort found a relative decrease in the risk
of incident HPV infection among women who re-
ported consistent condom use (37.8/100 patient-
years) relative to women reporting condom use
< 5% of the time (89.3/100 patient-years).58 The
non-zero transmission among consistent condom
users likely reflects the difficulty in preventing
transmission given the widespread genital epithe-
lial surfaces that are infected (e.g. scrotom, per-
ineum, vulva). Interesting, when sampling under
the fingernails of university men, these same in-
vestigators reported a 31% cumulative 24-month
incidence of HPV,30 suggesting the possibility for
transmission in the absence of genital-to-genital
contact; however, the extremely low prevalence
of HPV in female virgins suggests that this is 
not common.59
Though many women with genital HPV in-
fection do not have detectable abnormalities, the
epidemiology of HPV infection of the genital
tract seems to account for epidemiology of cervi-
cal tumors, including dysplasias that occur prior
to carcinoma of the cervix.60 Analyses performed
in the 1980s failed to illustrate a strong connec-
tion between HPV infection and cervical tumors.
Such conclusions were based on false-positive
and false-negative HPV DNA results obtained
using partially validated assays. After developing
validated HPV DNA assays,61,62 numerous stud-
ies have consistently shown that infection with
high-risk HPVs is a major risk factor for advanced
cervical dysplasia and invasive carcinoma.44,60
Based on many studies, cytologically normal
women that are HPV-positive are at a higher risk
for developing abnormalities than HPV-negative
women.46,63,64 Furthermore, a validated serologic
assay that was able to identify individuals that
were currently infected and previously infected
suggested that HPV-16 and related viruses were
likely causes of cervical cancer.65
The average genital infection clears in less than
6 months, as most genital infections are self-
limiting.43,49,66,67 An individual who has cleared
the HPV infection appears to return to the same
low risk of cervical intraepithelial dysplasia (CIN)
grade 3 or invasive carcinoma as an individual
who has not previously been detected to have
HPV. Low-grade dysplasia can be caused by in-
fection with low-risk or high-risk HPV types. Per-
sistent infection with high-risk HPV types, which
HPV epidemiology
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Figure 2. Rates of cervical HPV infection as associated with
age. The percentage of HPV infection with normal cytology
is much greater than HPV infection with cancerous cytology.
HPV infection cases among older populations are generally
less than HPV infection among younger populations. CIN 3
is highest in women who are older than the populations of
women in which the highest incidence of infection occurs.
(Reproduced from Reference 46 with kind permission from
Springer Science and Business Media.)
occurs in a marginal number of women with HPV
infection, is the single most significant risk factor
for the progression to CIN grade 3 or invasive
carcinoma (for review, see reference 68). It is 
not completely clear how long an infection must
continue before being affirmed persistent, but
given an average duration of transient HPV of
6–9 months, persistence is usually defined as in-
fections in which the same HPV type is identified
in two genital samples taken over an interval at
least 12 months apart. In most cases, of the vari-
ous HPV types, infection with HPV type 16 is
more likely to persist.69 Persistence alone, how-
ever, is not enough to cause progression to high-
grade dysplasia since persistent infection with
low-risk HPV types are less likely to progress
than high-risk HPV types.21 The specific activities
of high-risk HPV proteins E6 and E7 are likely to
represent, in part, explanations of the probability
of progression. Studies indicate that women with
higher viral loads are more likely to progress to
high-grade dysplasia,70,71 but not all evidence
supports this conclusion.72 Single measures of
high viral load using type-specific quantitative
methods are associated with prevalent CIN, but
do not necessarily predict disease progression.73
However, sustained high viral load measured in
serial samples is associated with virus and lesion
persistence.74
Since persistent infection with high-risk HPV
types represents the major risk factor for malig-
nant progression and high-risk HPV DNA is
found in almost all cases of cervical carcinoma,75
it is concluded that HPV infection is required for
cervical cancer. Persistent HPV infection alone,
however, is not enough to cause cancer because
certain individuals with persistent infection with
high-risk HPV may not develop serious lesions.
Natural history of cervical cancer
Most cervical cancer occurs in the transformation
zone. This is the region where the columnar ep-
ithelium of the endocervix meets the stratified
squamous epithelium of the exocervix.76,77 In
this region, cells are constantly proliferating,
making viral entry into the genome of the host
cell easier. About 85% of cancers of the cervix 
are squamous cell cancers. The other cases are
primarily adenocarcinomas, with a few being
small cell neuroendocrine tumors.
A series of dysplastic changes over a period of
many years accompanies the malignant progres-
sion of lesions to squamous cell carcinomas
(SCCs).76–78 The degree to which the squamous
epithelium is replaced by basaloid cells deter-
mines severity of lesions. For the most severe
dysplasias, basaloid cells have replaced the entire
thickness of the lesion. Pap smears of cervical
dysplasia reveal exfoliated basal cells and koilo-
cytes, which are cells with a wrinkled nuclei 
surrounded by a clear halo, as a result of the in-
fection. The histologic classification of cervical
dysplasias is CIN grades 1, 2 and 3, which corre-
spond to mild, moderate and severe dysplasias.
CIN 3 also covers in situ and invasive carcino-
mas. In the cytologic Bethesda System,79 mild cy-
tologic abnormalities are classified as low-grade
squamous intraepithelial lesions (LSIL) and more
severe abnormalities are classified as high-grade
SIL. Atypical squamous cytology of undetermined
significance (ASCUS) is the cytologic designation
for equivocal lesions.
Most dysplasias tend to spontaneously resolve.
In fact, the probability of resolution is consider-
ably high when the dysplasia is of low severity,
although it decreases with increased severity of
the dysplasia. Figure 3 illustrates the concept that
though the number of cases of HPV infection of
low severity are high, these lesions have a higher
probability of spontaneous regression, leading to
fewer cases of lesions of greater severity that have
a lower probability of spontaneous regression.37
Generally, severe dysplasias arise from less dys-
plastic lesions that have continued for several
years,80,81 though a few severe dysplasias have
been shown to rapidly develop without passing
through a low-grade stage.63 The characteristically
long interval between the development of cervi-
cal dysplasia and the onset of invasive cancer pro-
vides ample opportunity for screening programs
to identify premalignant lesions. Thus, regular and
timely testing as well as follow-ups of women
T. Hoory, et al
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with dysplastic lesions and appropriate treatment
can help prevent the development of most cervical
cancer cases. Adenocarcinoma and adenosqua-
mous cell carcinoma cases have been increasing
in number in countries with screening programs,
however. Thus, Pap smear screening may not be
as effective in identifying the precursors to these
tumor types.82–84
Of the more than 200 types of HPV, about 
40 can infect the genital tract. A subset of these
types is consistently found in cervical cancers, and
in a higher proportion than in controls. These
types are designated as high-risk types. Other HPV
types whose incidence rates in both tumors and
controls do not differ are designated as low-risk
types. In a worldwide study of almost 1000 cervi-
cal cancers from paraffin-embedded sections, over
90% contained HPV DNA.85 These results con-
firmed observations made in more restricted cer-
vical cancer studies.44 Four HPV types (16, 18,
31, 45) out of the 20 types uncovered in this study
were found to cause 80% of the HPV-positive
cancers. HPV type 16 was the most common type
found. On the other hand, low-risk HPV types 
(6 and 11) were found in only two of the tumors.
When a follow-up re-evaluation of the tumors
that were initially found to be HPV-negative was
performed, it was found that these results were
false-negative or that the DNA was too degraded
for the results to be considered reliable.75 The
major conclusion from this re-evaluation is that
at least 99.9% of cervical cancers contain HPV
DNA. Additional cervical cancer studies on a
group of CIN3 and invasive cancer patients also
supported the conclusion that virtually all cervical
cancer cases can be linked with HPV DNA.86
International analysis of squamous cell can-
cers pooled from 11 cases studies (1918 cases vs.
1928 controls) identified 15 HPV types as high-
risk, three additional types as probable high-risk
types and 11 low-risk types. Table 3 summarizes
the phylogenetic and epidemiologic classification
of HPV types, based on their association with cer-
vical cancer. Close to 91% of the cases were found
to be HPV DNA-positive. Of the HPV-positive
cases, eight types (16, 18, 31, 33, 45, 52, 58, 25)
accounted for 95% of the cancers. The phylo-
genetic and epidemiologic classifications of the
HPV virus types, with the exception of types 70
and 73, matched perfectly. Similar findings were
obtained in a prospective population-based study
which used CIN3 as the endpoint.21
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Table 3. Epidemiologic and phylogenetic classification of HPV types
Epidemiologic Phylogenetic classification
classification High-risk types Low-risk types
High risk 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 82 73
Probable high risk 26, 53, 66
Low risk 70 6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81, 89
Infection with HPV
Subclinical HPV infection
10,000,000 US cases/yr
Low grade dysplasia
2,000,000 US cases/yr
20–30%
HPV types
16 & 18
60–70%
HPV types
16 & 18
High grade
dysplasia
300,000 US cases/yr
Cancer
11,000 US
cases/yr
Spontaneous regression
Many years (15+)
Figure 3. Natural history of cervical human papillomavirus.
The approximate number of HPV cases in the United States
per year based on the varying degrees of infection. Most of
the lower grade dysplasias regress spontaneously, as well
as a few high-grade dysplasias. As the infection progresses
from low-grade to high-grade dysplasias, a higher percent-
age of cases are associated with HPV types 16 and 18.
(For review, see Reference 37.)
HPV types 16 and 18 can account for about
70% of all cervical cancer. HPV type 16 is the most
oncogenic type, followed by type 18 as the next
most virulent. Asymptomatic, prevalent HPV in-
fections in women were followed over a 10-year
period. It was found that both HPV-16 and -18
infections were more likely to progress to grade 3
CIN or invasive carcinoma and at a more rapid
rate compared to the other HPV types.87 Figure 4
illustrates the incidence rates of high-grade dys-
plasia in these women, grouped according to
HPV type 16, 18 or other high-risk or low-risk. 
A meta-analysis of published studies that com-
pared the frequency of HPV types in low-grade
squamous intraepithelial lesion to their frequency
in invasive squamous cell cancer found similar
results.88 When the 1918 cases of the interna-
tional study were compared with the 1928 con-
trols, the odds ratio for developing HPV type
16-associated cervical cancer was 434 and for de-
veloping HPV type 18-associated cervical cancer
was 248.20 These are among the highest odds 
ratios for human carcinogens.
Although most studies have been conducted
on the more common squamous cell cancers,
adenocarcinomas and adenosquamous carcino-
mas,89,90 certain carcinomas with neuroendocrine
differentiation have also been shown to contain
HPV DNA.91 A recent international analysis pooled
eight case-control studies from non-SCCs and
found that 81% of these tumors were HPV 
DNA-positive, all of which were attributable to
HPV-16 or HPV-18.90 A higher fraction of these
glandular tumors were associated with HPV-18
compared to SCCs.
Although there is considerable utility for dis-
tinction between high-risk and low-risk HPV
types, the distinction is not inviolate. HPV type
classification is based on an assumption that the
frequency of exposure and infection has been
constant over many years. However, this condi-
tion may not be warranted in certain instances.
For example, some low-risk HPV types are infre-
quently associated with cervical cancer.92 Low-risk
HPV types such as 6 and 11 that were isolated
from cervical cancers may have alterations in their
genome which possibly increased their oncogenic
potential or an HPV type may have increased
oncogenicity in an immunocompromised host.
Also, the classifications of high-risk and low-risk
HPV types may not apply to HPV infection in all
sites. For example, with a low-grade SCC, the
Buschke-Lowenstein tumor, which invades the
external genitalia, is normally associated with the
low-risk HPV types 6 and 11.93,94 Low-risk types
may also be involved in laryngeal cancer compli-
cating recurrent respiratory papillomatosis.
Other cofactors in cervical cancer
It is clear that although HPV infection of the high-
risk types is required for cervical carcinogenesis,
it is not sufficient. There are other factors that
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Figure 4. Cumulative incidence of high-grade cervical 
lesions (≥ CIN 3) over a period of 10 years. 
The population of the study is 20,500 HPV-positive
women who have been assessed as HPV-positive at
study entry. HPV types were also assessed and grouped
as HPV-16, -18, other high-risk, and non-high-risk.
(Modified with permission from Reference 87.)
must cooperate with the infection before cancer
arises from HPV-positive tissue. Changes such as
integration of viral DNA (which stabilizes the
high expression of E6 and E7) are virus specific,
and are associated with the malignant progression
of the tumor. Other changes include the alteration
of cellular genes, leading to downregulation of
tumor suppressor genes and proapoptotic genes
or upregulation of proto-oncogenes or antiapo-
ptotic genes. These alterations reflect the effects of
prolonged viral gene expression, in particular viral
proteins E6 and E7.23,24,95,96 These changes are
diverse, yet some of them occur quite frequently.
There have also been some reports of epigenetic
silencing of a number of genes in high-grade 
dysplasias and carcinomas.97–99
Since only a few women that are infected
with high-risk HPV develop malignant tumors,
host and environmental factors have been studied
for their potential influence on the occurrence of
cervical cancer and precursor lesions.57,100 Factors
such as pregnancy, high parity, long duration
oral contraceptive use, smoking, micronutrients,
and other sexually transmitted diseases101 have
been found to be independently associated with
an increased cervical cancer risk after adjustment
for HPV infection. In many instances, how the
cofactor contributes to development of dysplasia
to malignant tumors is not clear. The cofactor may
possibly increase the risk of establishing genital
infection, decrease the local or systemic immunity,
stimulate the growth of HPV-infected tissue or
induce mutations in the infected tissue. A poten-
tially relevant study found higher levels of a car-
cinogen originating from tobacco in the cervical
mucus of cigarette smokers than nonsmokers.102
Certain studies show a hereditary contribution
to cervical cancer risk.103,104 Although not every
study has found positive results, it appears that
specific alleles of certain immune response genes
are associated with protection from or suscepti-
bility to infection with HPV. Such alleles are
from human leukocyte antigen (HLA) class I and
II genes and killer immunoglobulin-like receptor
(KIR) genes, which recognize HLA antigen class I
alleles.100,105
HPV Infections in Other Genital Sites
Anogenital warts: condylomas
Just as cervical HPV infection is most widespread
among young, sexually active adults, so are con-
dylomas. The incidence rate of condylomas usu-
ally parallels that of other sexually transmitted
conditions.43,56 Prevalence in the United States 
is estimated to be 1% of the sexually active pop-
ulation aged 15–49 years. The mid-1960s saw 
an increase in sexual promiscuity, which was
linked with a fourfold increase in the incidence
of condylomas. This was paralleled by a similar
increase in HPV seroprevalence over the same
time period, supporting the epidemic of HPV in-
fection associated with the sexual revolution.106
Penile lesions commonly occur in sexual contact
with women with CIN, although infection may
be subclinical.107
Anogenital warts are usually external lesions
that grow in manifold. Generally, they may arise
anywhere on the external genitalia and in multi-
ple sites. In women, they occur most commonly
on the perineum and anus and in men on the
penis and anus. Multiple lesions may develop
around the anus, surrounding the anal canal.
Most condylomas are self-limiting and sponta-
neously regress or regress with local treatment.
However, some condylomas may persist for years.
Similar to other HPV infections, genital warts
can be quite resistant to treatment. They may
also become larger and more populated during
pregnancy and then regress after delivery. Such a
sequence of events may be a reflection of immune
suppression associated with pregnancy.
Of all cases of genital warts, about 90% is
caused by the closely related HPV types 6 or 11,
with type 6 predominating.108 Other HPV types
may also be found in genital warts such as HPV
type 16. Bowenoid papulosis is a related lesion.109
Condylomas normally consist of a number of
small papules which histologically resemble SCC
or Bowen’s disease in situ. Numerous lesions of
this sort contain HPV-16, yet the rate of pro-
gression to definite malignancy is lower than for
cervical lesions. In children, some genital warts
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may be sexually transmitted, secondary to sexual
abuse.110,111 Commonly, in children, virus inocu-
lation at birth may lead to genital lesions or they
may arise from the occasional spreading of cuta-
neous warts. Unlike anogenital lesions found in
adults, a considerable number of genital warts
found in children contain HPV DNA that is nor-
mally found in nongenital warts. Thus, it may 
be possible that genital skin in children is more
vulnerable to infection with nongenital HPV types.
Vulvar, vaginal and penile malignancies
Genital HPV can infect areas of the genital tract
other than the cervix that contain stratified squa-
mous epithelium. At these other genital sites, the
relative risks associated with infection with HPV
are close to those of cervical cancer, though the
absolute incidence of these tumors is consider-
ably lower.44 A subset of cancers of the vulva,
vagina and penis have HPV DNA, normally HPV-
16. Giant condyloma acumina (also called the
Buschke-Lowenstein tumor), a low-grade, locally
invasive SCC, involves the external genitalia, many
times the penis. This condyloma is linked with
low-grade HPV types, including 6 and 11.93,94
The invasive SCC of the vulva, morphologi-
cally designated as warty or basaloid, generally
arise in younger women. These tumors contain
HPV DNA, in particular HPV-16.33,44 Possible 
cofactors for vulvar cancer include smoking and
infection with HSV (herpes simplex virus) type 2.
Vulvar and vaginal dysplasia are more common
in women with a previous history of cervical dys-
plasia112 and there is evidence that these dysplas-
tic cells may have the same origins as cervical
tumors.113 Only a few vulvar SCCs, in contrast to
basaloid vulvar cancers, exhibit HPV DNA, and
these HPV-negative tumors often have p53 muta-
tions and occur more frequently in older women
(for review, see reference 114).
Anal cancer
There are some major similarities as well as sig-
nificant differences between anal cancers and
cervical cancers. Anal cancer is more frequent in
women than in men, with the number of cases
per year in women almost twice that of men in
the United States.115 The occurrence of anal can-
cer in women increased in the 1980s and has not
changed, while the incidence in men has steadily
increased since the 1980s.56 In most cases, anal
infection with HPV is sexually transmitted, and
the risk for cancer is increased in cases with a his-
tory of receptive anal intercourse in women and
homosexual activity in men.116 In many cases, a
history of anal intercourse is lacking, suggesting
that it is quite likely that a number of anal infec-
tions have spread from other areas of the genital
tract. An observation, which lends support to this
interpretation, is the common occurrence of si-
multaneous cervical and anal infection, often with
the same HPV.29 Anal infection with HPV occurs
at a similar rate to cervical infection, yet the for-
mer has not been studied as systematically as have
infections of the cervix.117 High-risk HPV has been
found in many anal cancers, as in cervical cancer,
with a greater number of anal cancers being
caused by HPV-16. Anal cancers mostly arise in
the transition zone between columnar and squa-
mous epithelium. A Scandinavian study revealed
HPV-16 in 83% of the HPV-positive anal tumors,
with over 90% of the tumors in women and 69%
of the tumors in men being caused by HPV.116
Thus, it appears that some anal cancers in men
may not be attributable to HPV, whereas most
anal cancers in women are attributable to HPV.
The risk of anal cancer appears to be much
lower for the general population than cervical
cancer, yet the reason for these differing rates is
uncertain. Cervical cancer screening programs that
are available in certain countries do not allow 
for an effective comparison between anal cancer
and cervical cancer risks of progression because
such programs prevent cervical cancer develop-
ment.118 Pap smear screening in underdeveloped
countries, on the other hand, has little or no im-
pact on the incidence of cervical cancer. In these
countries, anal cancer occurs at less than one
tenth the frequency of cervical cancer.
Human immunodeficiency virus (HIV)-positive
individuals have a higher risk of anal cancer than
the general population, and the risk is particularly
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higher for HIV-positive homosexual males. Based
on the AIDS-Cancer Match Registry Study in the
US, HIV infection was associated with a relative
risk for invasive anal cancer of 37.9 for men and
6.8 for women.118 This difference was attribut-
able to the HIV-positive homosexual men group.
The relative risk for homosexual men that were
HIV-positive was 59.5 and 5.9 for HIV-positive
males that used intravenous drugs. A high propor-
tion of HIV infected men and women also have
anal HPV infection.32 Anal infection with HPV of
HIV-positive male homosexuals was 93% com-
pared to 61% of HIV-negative homosexual males
and 76% of HIV-positive women, based on stud-
ies from San Francisco. Therefore, it is unlikely that
an increased risk of anal cancer occurs in male
homosexuals resulting from higher numbers HPV
infection. It is more reasonable that a feature of
anal intercourse such as trauma interacts with HIV
and HPV infection and leads to anal cancer.118
There is evidence that some of the increased risk
of male homosexuals to anal cancer was prior to
the HIV era, an observation which supports this
interpretation.119 The high risk in homosexual and
bisexual men for anal cancer has thus led investi-
gators to suggest screening of this population for
anal squamous epithelial lesions.
HPV Infections of the Aerodigestive Tract
Infections of the oral cavity
Benign lesions are commonly observed in pa-
tients with HPV infection of the oral cavity.120,121
These infections may be asymptomatic or may
lead to single or multiple lesions in any area of
the oral cavity. HPV types 6, 11 and 16 and other
genital-mucosal HPV types have been found in
the oral tissue. At least half of the lesions in the
oral cavity of papillomatous morphology are usu-
ally HPV positive. Most benign oral lesions seem
to be caused by HPV types 6 and 11, although
type 16 may lead to some benign oral lesions.
Focal epithelial hyperplasia (FEH) is a well-
defined clinical entity found only in the oral 
mucosa. FEH is most prevalent in indigenous
populations of Central and South America, as
well as Alaska and Greenland. The Eskimo popu-
lation of Greenland has a varied prevalence of
FEH in different areas, ranging between 7% and
36%. On the other hand, the prevalence of FEH
among Caucasian residents was 1 in 300.122 Most
of the oral infections are attributed to HPV types
13 and 32, which are found primarily in oral 
cavity infections. Newborns may acquire genital-
mucosal HPV types by maternal transmission,
however, this occurrence is mostly relevant to 
recurrent respiratory papillomatosis.123
Head and neck cancers
Two well-known risk factors for head and neck
cancer are alcohol consumption and cigarette
smoking. Though HPV infection is not generally
involved in cancers of the head and neck, evidence
indicates that at least a subset of oral cancers are
HPV-positive.124–128 Type 16 is associated with
about 90% of oral tumors which are HPV-positive.
Many of the cancers are in the oral pharynx, in-
cluding the base of the tongue, the soft palate, the
tonsils and the tonsillar fossa. The incidence of
these cancers in the US increased approximately
2% each year from 1973 to 1995. This increase is
most likely the effect of the increase in HPV in-
fection by sexual transmission.129 A risk factor
for these tumors may be genital-oral sex, and the
risk of HPV infection and cigarette smoking may
be more than additive.130 In general, HPV-positive
tumors tend to have basaloid morphology, are
less likely to have Rb or p53 mutations and more
likely to express p16. These tumors may also
have enhanced disease-specific survival.
Recurrent respiratory papillomatosis
(laryngeal papillomatosis)
Recurrent respiratory papillomatosis (RRP), also
called laryngeal papillomatosis, is an uncommon
condition, which can compromise the airway, 
especially in children.131–133 Genital HPV types,
particularly types 6 and 11, can also cause lesions
in the respiratory cavity. Vocal cords of the larynx
seem to be the most commonly affected area,
though the trachea, lungs, nose and oral cavity
HPV epidemiology
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are other sites that can be affected. Generally, the
treatment for symptomatic papillomas is surgical
removal; however, recurrence of the disease would
require repeated surgical treatment. It is impor-
tant to avoid the necessity of tracheostomy in
RRP patients since papillomas may grow next to
the tissues involved in the tracheostomy, leading
to morbidity. It was estimated in the year 2000
that a typical case of juvenile-onset RRP cost
$200,000, and the country’s cost of RRP was 
between $40 and $123 million.134
From studies in epidemiology, RRP develops
by at least two different modes.135,136 Young chil-
dren are primarily affected via the first mode,
and in the second, RRP is first diagnosed in older
individuals. RRP can occur at any age, but the risk
of developing RRP decreases after the age of 5.
History of genital warts in the mother is a risk
factor for children under 5. A study in Denmark
revealed that 1% of children with mothers who
had genital warts developed RRP. This percentage
corresponded with a 231 times higher risk of RRP
development compared with children of women
without such a history.137 Increased risk is associ-
ated with first pregnancy and young aged mothers,
while lower risk is associated with cesarean sec-
tion.136 A contributing factor is polymorphism
of HLA class II. Those cases of RRP arising in the
early years of childhood are likely to be related
to intrapartum HPV transmission or, more rarely,
in utero transmission. In adult RRP, a risk factor
may be a history of oral-genital sex.
Although HPV type 6 is a more prevalent cause
for genital warts than type 11, the opposite is true
for RRP. Furthermore, type 11 may also be asso-
ciated with more severe cases.132,138–140 The one-
time exposure to HPV during vaginal delivery and
the variable latent period before onset of RRP of
up to 5 years remains to be explained.54 A possible
explanation is that viral latency may have been
established in neonates exposed to HPV before
the onset of infection. Latency has been shown
in the larynx of RRP patients in remission.131
RRP could also be associated with a low risk
of progression to severe dysplasia or cancer, and
spread to bronchi and lungs.141 If the papillomas
are subjected to X-irradiation, the risk of progres-
sion is increased. X-irradiation was a common
treatment in the 1940s. Unlike cervical cancer,
HPV types 6 and 11 in RRP are distinctly linked
with severe dysplasia and cancer, with type 11
being more prevalent. In addition, HPV type 16
is sometimes found in cases of laryngeal cancer
not associated with RRP.141
HPV Infections of Non-genital Skin
Non-genital skin warts
Non-genital skin warts can occur in almost any
non-genital area of the body,142,143 though they
commonly occur on the feet and hands. These
warts are benign papillomas and occur frequently
in older children and young adults.144,145 Some
studies of school-aged children showed 10% of this
population to be affected.146 It has been shown
that papillomaviruses that cause non-genital skin
warts are not affected by desiccation.147 A com-
mon occurrence for non-genital warts is the trans-
mission through fomites; in their environment,
the papillomaviruses can remain infectious for
long periods.148 Maceration of the skin may cause
it to be predisposed to infection, allowing papil-
lomavirus to reach the basal cells, a necessary
step for the virus to establish an infection. Once
the infection is established, multiple symmetric
or unilateral lesions are generally observed. Auto-
inoculation is most likely the cause of lesions,
which develop in the mucous membrane. Though
infections may persist for a few months and re-
gress spontaneously within a few years, some
persist indefinitely.
The immune system is thought to play a role
in the regression of lesions. There may be a 
low level of mononuclear infiltrating cells that
contribute to spontaneous regression, although
spontaneous regression of certain skin lesions such
as flat warts may be linked with a higher level of
infiltrating erythrocytes. Older-aged individuals
may have developed some immune resistance to
infection since there are a low number of cases in
this population.
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There is a reasonable correlation between HPV
types and the type of clinical lesion. Common
warts, plantar warts, and mosaic warts are gener-
ally associated with HPV types 1, 2, 4, 27, 57 and
65, whereas flat warts are commonly associated
with HPV types 3, 10, 28 and 41. Butchers and
meat handlers may have an unusually high preva-
lence of hand warts. Though one may expect that
animal papillomavirus might be a common cause,
HPV type 7 is normally found in these hand
warts. Most likely, maceration and skin trauma
predispose these workers to infection with HPV
type 7 when they are exposed to the virus.
EV
EV is a rare disorder in which infection of in-
dividuals leaves them susceptible to cutaneous
HPV infection.149,150 In childhood, warts gener-
ally develop, become widespread, do not tend to
regress, and, in certain cases, may develop into
squamous cell cancers. There are two predomi-
nant types of lesions normally seen, both of
which can occur in the same patient. Certain le-
sions have the appearance of flat warts, whereas
others are flat, scaly, red-brown macules. Flat
warts are caused by the same HPV types that in-
duce flat warts in the general population, which
are usually HPV-3 and HPV-10. The scaly lesions
are associated with EV-specific HPV types, most
frequently HPV-5 and HPV-8. Patients with EV
are frequently infected with several HPV types.
EV occurs as an inherited disorder in about
half of the affected patients. Numerous families
have a history of parental consanguinity. In most
affected families, EV appears to be inherited in
an autosomal recessive pattern. One family, how-
ever, with apparent X-linked recessive inheritance
has been described. These cases are genetically
heterogeneous because the condition in different
families has been mapped to two different 
chromosomal loci.151 In some EV families, two
novel genes with nonsense mutations, EVER1
and EVER2, have been molecularly identified at
one of these chromosomal loci (17q25).152
EV patients are not ordinarily more suscepti-
ble to clinical infection by other microbial agents
including HPV associated with common warts or
mucosal HPV. Quite a few healthy individuals
have harbored EV-specific HPV types in normal
skin. Thus, patients with EV are unusual in that
these HPV types produce clinically apparent le-
sions. These lesions are resistant to the custom-
ary treatment modalities. Overall deficiencies in
immune system function can be shown in most
patients with EV. Furthermore, acquired EV has
been associated with HIV infection153 and clini-
cal lesions associated with EV-specific HPV types
have been associated with immunosuppressed
individuals.154
Of the EV patients, about one third develops
skin cancers associated with their lesions. Although
distant and regional metastases may occur, most
malignant tumors remain local. Risk of progres-
sion to malignant tumors is limited to pityriasis-
like lesions, which are lesions that contain EV.
HPV types 5 and 8 appear to be the most onco-
genic, since about 90% of the skin cancers con-
tain either of the two types. The cancers develop
on the areas of the skin that are exposed to the
sun, which implies that carcinoma of the skin
develops in EV patients as a result of the combi-
nation of EV HPV types and the co-carcinogen,
UV light. Also common in EV-associated cancer
are p53 mutations,155 which are not found in
mucosal cancers associated with HPV.
Nonmelanoma skin cancer
Nonmelanoma skin cancers (NMSC) are ex-
tremely common and they typically arise on ex-
posed areas of the skin, with sunlight exposure
as a primary risk factor. NMSCs are normally
subdivided into SCC or basal cell carcinoma
(BCC). Nonmelanoma tumors that are associ-
ated with sunlight are generally locally invasive
and do not metastasize. Immunosuppressed in-
dividuals have a high risk of developing warts,
premalignant lesions and NMSC, particularly the
SCCs in sun-exposed skin.156–158
For those NMSC patients without EV, HPV may
still be the etiologic agent based on the onco-
genic potential of HPV and the predisposition to
certain types of HPV infection in SCC patients
HPV epidemiology
J Formos Med Assoc | 2008 • Vol 107 • No 3 211
with EV. Using nested PCR and other sensitive
techniques to detect viral DNA, about 60–80%
of NMSC in immunosuppressed patients were
HPV positive and about half as many tumors
were HPV positive in immunocompetent pa-
tients.159–161 Though many HPV-positive patients
have EV, the percentage of tumors where HPV is
considered the etiologic factor is unclear. The 
relevant HPV types in NMSC have not been well
defined. The clinical tumors with HPV are not
pathologically distinct from those tumors with-
out HPV, unlike other mucosal or anogenital can-
cers. High numbers of HPV DNA copies may be
found in only a minor proportion of NMSC cases,
which also express viral RNA. However, in the
larger proportion of NMSC cases, less than one
copy of HPV DNA in each cell is normally found;
this conclusion is based on the necessary high
level of sensitivity of DNA detection techniques.
Thus, it is implied that HPV may not be required
for the maintenance of the tumors after neces-
sary infection to induce the tumor.162 Another
possibility is that HPV DNA detection is second-
ary to the primary cause of the tumor, which may
not render HPV as the etiologic agent. Along these
lines, healthy skin can sometimes contain HPV,
particularly EV types, only as a collaborator in
producing lesions16,163 and removal of top layers
of these lesions has resulted in a considerable 
decrease in the numbers of NMSC lesions.164
Summary
Significant progress has been made in the field
of HPV molecular epidemiology over the past 10
years. The understanding of HPV as an etiologic
factor for several important cancers, such as cervi-
cal cancer and other anogenital cancers has led to
HPV testing for screening and diagnosis of some
HPV-associated diseases. In addition, this under-
standing has also facilitated the development of
preventive and therapeutic HPV vaccines as well
as other therapeutic interventions. Since HPV in-
fection is known to be a necessary but not suffi-
cient factor for carcinogenesis of HPV-associated
malignancies, it is conceivable that future endeav-
ors will focus on other cofactors that contribute
to the etiology of carcinogenesis in HPV-associated
diseases. A better appreciation of these cofactors
will facilitate our understanding of the patho-
genesis of HPV-associated lesions, thus leading
to better prevention, diagnosis and treatment of
HPV-associated malignancies.
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